cefixime has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liberto, MC | 1 |
| Berlinghieri, MC | 1 |
| Muleo, G | 1 |
| Molica, S | 1 |
| Focà, A | 1 |
1 other study available for cefixime and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Cefixime does not affect polymorphonuclear cell and monocyte functions from chronic lymphoid leukemia patients and from healthy donors.
Topics: Administration, Oral; Cefixime; Cephalosporins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mono | 1991 |